Table 4.

Univariate and multivariate analyses for prognostic significance of clinical features and molecular subtypes in patients with primary small cell lung cancer.

Variables	OS				DFS
	Univariate analyses	P	Multivariate analyses	P	Univariate analyses	P	Multivariate analyses	P
	HR (95% CI)		HR (95% CI)		HR (95% CI)		HR (95% CI)
Clinical markers
Age, ≥65 v. <65 years	1.284 (0.720-2.290)	0.397			1.152 (0.672-1.978)	0.606
Gender, female v. male	0.533 (0.295-1.095)	0.087	0.233 (0.052-1.051)	0.058	0.583 (0.302-1.127)	0.109
Smoking, smoker v. non-smoker	2.069 (1.929-4.606)	0.053	4.349 (0.960-19.691)	0.056	2.258 (1.027-4.966)	0.043	2.881 (1.039-7.986)	0.042
Preoperative ChT, yes v. no	1.118 (0.522-2.394)	0.775			0.911 (0.474-1.751)	0.780
Pathological stage, I-II v. III	0.774 (0.400-1.501)	0.449			0.953 (0.534-1.702)	0.872
No. of adjuvant ChT, ≥4 v. <4	0.340 (0.190-0.609)	0.000			0.515 (0.302-0.879)	0.015
Brain metastasis, yes v. no	3.243 (1.710-6.148)	0.000			4.503 (2.515-8.064)	0.000	2.711 (1.290-5.701)	0.009
Lung metastasis, yes v. no	2.453 (1.125-5.348)	0.024			3.661 (1.863-7.195)	0.000	2.610 (1.185-5.748)	0.017
Liver metastasis, yes v. no	7.566 (3.139-18.235)	0.000	2.975 (1.036-8.541)	0.043	4.108 (1.903-8.866)	0.000
Bone metastasis, yes v. no	2.365 (1.181-4.738)	0.015	2.445 (0.977-6.118)	0.056	4.206 (2.289-7.728)	0.000
Adrenal metastasis, yes v. no	3.626 (1.371-9.589)	0.009			2.301 (0.971-5.455)	0.058
Molecular subtypes	0.652 (0.498-0.855)	0.007	0.599 (0.420-0.853)	0.005	0.601 (0.468-0.773)	0.000	0.640 (0.461-0.888)	0.008

ChT, chemotherapy; OS, overall survival; DFS, disease-free survival; HR, hazard ratio; CI, confidence interval; ASCL1, achaete-scute homologue 1; NEUROD1, neurogenic differentiation factor 1; POU2F3, POU class 2 homeobox 3; YAP1, yes-associated protein 1.